Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Bhag Karamchandani who wrote (4173)	4/28/1998 11:28:00 AM
From: Henry Niman	Respond to of 6136

There was a Phase III club report that came out some time ago (6-12 months). For a fee, it can be accessed at wsj.com . I uploaded the report onto the LGND thread, but don't have the exact date. You might be able to find it with an Alta Vista search (SI is searchable, but for some reason, I'm not sure that all posts are accessed). LGND was a prominent club member. They have just finished Phase III for topical Panretin (for KS) with an NDA filing within a few weeks, are winding up Phase III for oral and topical Targretin (for CTCL) with NDA filings slated for the end of this year, beginning of next year, planning on finishing phase III on oral Panretin next year (for KS and APL) with NDA filing next year, and have oral Targretin in Phase III trials for lung and breast cancer. The status of their extremely impressive pipeline can be seen in their new annual report. A representative table is at home.att.net